Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease (Breathtec Biomedical)
Nash Pharmaceuticals Inc., a wholly owned subsidiary of UF startup Breathtec Biomedical Inc., is pleased to announce that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories. NP-160 is one of a number of […]
Breathtec Provides Update on FAIMS Breathalyzer Development Program (Globe Newswire)
UF startup Breathtec Biomedical Inc. is pleased to report on the development of its Breathtec Disease Detection Breathalyzer prototype (V3) based on the FAIMS (field asymmetric waveform ion mobility spectrometry) technology. The company announced that it has amended its research agreement with the University of Florida’s Analytical Chemistry Department, where Dr. Richard Yost, the principal […]
Breathtec Provides Nash Pharmaceuticals’ Plans for Next Year (Globe Newswire)
UF startup Breathtec Biomedical Inc. is pleased to provide details on Nash Pharmaceutical’s plans for the next 12 month period. Breathtec recently announced that it has signed a letter of intent to acquire 100 percent of the shares of Nash Pharma. Nash Pharma is a clinical stage pharmaceutical development company focused on drug repurposing in […]
Breathtec to Open New Drug Development Division, Signs LOI to Acquire 100% of Clinical Stage Nash Pharmaceuticals Inc. (Globe Newswire)
UF startup Breathtec Biomedical Inc. is pleased to announce that it will be opening a new drug development division and has signed a Letter of Intent (“LOI”) to acquire 100% of the shares of Nash Pharmaceuticals Inc. Nash Pharma is a clinical stage pharmaceutical development company focused on drug repurposing in the areas of non-alcoholic […]